On 11 April 2024, Novartis BidCo, Basel, Switzerland, ("Bidder") has published the offer document regarding its takeover offer (cash offer) to the shareholders of MorphoSys AG, Planegg, Germany ("MorphoSys") for the acquisition of all no-par value bearer shares (ISIN DE0006632003) ("MorphoSys Shares") including all no-par value bearer shares represented by American Depositary Shares (ISIN US6177602025) ("MorphoSys ADS") in MorphoSys against payment of a cash consideration in the amount of EUR 68.00 per MorphoSys Share. The acceptance period of the offer will expire on 13 May 2024, 24:00 hours (local time Frankfurt am Main, Germany) and 18:00 hours (local time New York, United States of America), unless it is extended pursuant to the applicable rules under the WpÜG.
As of 12 April 2024 ("Reference Date"), i.e. after the publication of the offer document and prior to the publication pursuant to section 23 para. 1 sentence 1 no. 2 WpÜG, the Bidder acquired 2,023,370 MorphoSys Shares on the stock exchange. The highest price paid was EUR 67.95 per MorphoSys Share. The transfer of the 2,023,370 MorphoSys Shares to the Bidder is expected to take place within the next few days.
The aggregate number of MorphoSys Shares for which purchase agreements were entered into on the Reference Date represents approx. 5.36 % of all MorphoSys Shares in existence on the Reference Date and approx. 5.37 % of all MorphoSys Shares in existence, other than treasury shares held by MorphoSys, on the Reference Date.